Skip to main content

Table 2 Site-wise results of therapeutic efficacy and parasite clearance in studies of the National Antimalarial Drug Resistance Monitoring System, northeast India, 2012-2013

From: Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India

    

Therapeutic efficacy

PCT (hours)

State/UT

District/city

Drug

n

ACPRa

ETFb

LCFc

LPFd

LFU

WTH

PV

PF*

Surv

95% CI

< 24

24- < 48

48- < 72

≥ 72

Tripura

Gomati

ASP

77

43

4

3

8

0

8

1

10

74.1

61.0, 84.7

25

26

12

6

Mizoram

Lunglei

ASP

71

47

0

3

8

1

7

0

5

81.0

68.6, 90.1

47

15

1

0

Arunachal Pradesh

Changlang

ASP

42

22

0

2

4

0

5

0

9

78.6

59.0, 91.7

15

18

2

2

  1. Abbreviations: ACPR adequate clinical and parasitological response, ETF early treatment failure, LCF, late clinical failure, LPF late parasitological failure, LFU loss to follow-up, WTH withdrawal, PCT parasite clearance time, *PF P. falciparum re-infection, PV protocol violation.
  2. aAbsence of parasitaemia on day 28 without previous criteria for failure.
  3. bMarked by the following, alone or in combination: danger signs for severe malaria on day 1, 2 or 3 in the presence of parasitaemia; parasitaemia level on day 2 higher than on day 0; parasitaemia level on day 3 more than 25% higher than on day 0; parasitaemia on day 3 plus fever.
  4. cDanger signs for sever malaria and/or fever plus parasitaemia from day 4 to day 28.
  5. dParasitaemia from day 7 to day 28 even if patient afebrile.
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us